Feds accused a Wichita pharmacist of taking part in a drug conspiracy. Jurors agreed. BY AMY RENEE LEIKER

https://www.kansas.com/news/local/crime/article233072117.html

Wichita pharmacist convicted of unlawfully dispensing opioids

https://www.pratttribune.com/news/20190724/wichita-pharmacist-convicted-of-unlawfully-dispensing-opioids

Florida Board of Pharmacy Initiates Work on International Export Pharmacy Permit Application and Rules

https://www.jdsupra.com/legalnews/florida-board-of-pharmacy-initiates-57765/

Andover pharmacy under investigation for opioid dispensing

https://www.bostonglobe.com/business/2019/07/24/andover-pharmacy-under-investigation-for-opioid-dispensing/yBCeO3LE7WBq549RNVT9xN/story.html

Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals GlobeNewswire•July 24, 2019

https://finance.yahoo.com/news/adamis-pharmaceuticals-provides-litigation-belcher-130000544.html

Mandatory Public Drug Qua;ity Standards Increase Access to Biosimilars in Europe

https://www.usp.org/sites/default/files/usp/document/our-work/biologics/biosimilars-eu-white-paper.pdf

07/23/2019

07/22/2019

Curaleaf, Inc

Center for Drug Evaluation and Research

Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products

07/23/2019

07/16/2019

Indoco Remedies Limited

Center for Drug Evaluation and Research

CGMP/Finished Pharmaceuticals/Adulterated

07/23/2019

07/02/2019

High Chemical Company, Div of National Generic Distributors

Division of Pharmaceutical Quality Operations I

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety

Agency is expediting work to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD

Today, the U.S. Food and Drug Administration announced that it has issued a warning letter to Curaleaf Inc., of Wakefield, Massachusetts, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases. “As we examine potential regulatory pathways for the lawful marketing of products containing cannabis and cannabis-derived compounds like CBD, protecting and promoting public health remains our top priority. Selling unapproved products with unsubstantiated therapeutic claims — such as claims that CBD products can treat serious diseases and conditions — can put patients and consumers at risk by leading them to ...

Read More